| Drug General Information |
| Drug ID |
D02YVM
|
| Former ID |
DNCL003136
|
| Drug Name |
Zicronapine
|
| Drug Type |
Small molecular drug
|
| Indication |
Schizophrenia [ICD9: 295; ICD10:F20]
|
Phase 3 |
[1]
|
|---|
| Company |
Lundbeck
|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C22H27ClN2
|
| Canonical SMILES |
CC1(CN(CCN1C)C2CC(C3=C2C=C(C=C3)Cl)C4=CC=CC=C4)C
|
| InChI |
1S/C22H27ClN2/c1-22(2)15-25(12-11-24(22)3)21-14-19(16-7-5-4-6-8-16)18-10-9-17(23)13-20(18)21/h4-10,13,19,21H,11-12,14-15H2,1-3H3/t19-,21+/m0/s1
|
| InChIKey |
BYPMJBXPNZMNQD-PZJWPPBQSA-N
|
| CAS Number |
CAS 170381-16-5
|
| PubChem Compound ID |
|
| PubChem Substance ID |
16676298, 23603796, 42544573, 79419855, 135266807, 140419785, 163312359, 174494660, 198975150, 227170595, 244101005
|
| Target and Pathway |
| Target(s) |
D(2) dopamine receptor |
Target Info |
Modulator |
[2]
|
|---|
| Dopamine D1 receptor |
Target Info |
Modulator |
[2]
|
| 5-hydroxytryptamine 2A receptor |
Target Info |
Modulator |
[2]
|
|
KEGG Pathway
|
Rap1 signaling pathway
|
|
cAMP signaling pathway
|
|
Neuroactive ligand-receptor interaction
|
|
Gap junction
|
|
Dopaminergic synapse
|
|
Parkinson's disease
|
|
Cocaine addiction
|
|
Alcoholismhsa04020:Calcium signaling pathway
|
|
Amphetamine addiction
|
|
Morphine addiction
|
|
Serotonergic synapse
|
|
Inflammatory mediator regulation of TRP channels
|
|
PANTHER Pathway
|
Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
|
|
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
|
|
Dopamine receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathwayP05912:Dopamine receptor mediated signaling pathwayP04374:5HT2 type receptor mediated signaling pathway
|
|
PathWhiz Pathway
|
Dopamine Activation of Neurological Reward System
|
|
Reactome
|
Dopamine receptors
|
|
G alpha (i) signalling eventsR-HSA-390651:Dopamine receptors
|
|
G alpha (s) signalling eventsR-HSA-390666:Serotonin receptors
|
|
G alpha (q) signalling events
|
|
WikiPathways
|
Hypothetical Network for Drug Addiction
|
|
Monoamine GPCRs
|
|
GPCRs, Class A Rhodopsin-like
|
|
Genes and (Common) Pathways Underlying Drug Addiction
|
|
GPCR ligand binding
|
|
GPCR downstream signaling
|
|
Nicotine Activity on Dopaminergic NeuronsWP666:Hypothetical Network for Drug Addiction
|
|
GPCR downstream signalingWP733:Serotonin Receptor 2 and STAT3 Signaling
|
|
Serotonin Receptor 2 and ELK-SRF/GATA4 signaling
|
|
SIDS Susceptibility Pathways
|
|
Gastrin-CREB signalling pathway via PKC and MAPK
|
|
GPCRs, Other
|
| References |
| REF 1 | ClinicalTrials.gov (NCT01295372) Safety and Efficacy of Zicronapine in Patients With Schizophrenia. U.S. National Institutes of Health. |
|---|
| REF 2 | Clinical pipeline report, company report or official report of Lundbeck. |
|---|
